Scholarlink

Purpose <p>Heart failure (HF) burden and care varies significantly across different countries. We aimed to illustrate the clinical characteristics and HF-related care among cardiology inpatients in Greece.</p> Methods <p>We collected information about all cardiology inpatients on the 3rd of March 2022. The current analysis focuses on acute or chronic HF.</p> Results <p>Among a total of 923 participants, 280 (30%) concerned cases of acute HF whereas 351 patients (38%), (median age 79 ± 12&#xa0;years, male gender 63.8%) had a history of chronic HF, with their majority presenting with multiple comorbidities and previous HF hospitalizations. 173 (49%) of chronic HF participants had reduced LVEF. Ischemic heart disease was the predominant HF etiology (182, 51.9%). Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively. Independent predictors of lower prescription rates of Guideline Directed Medical Therapy (GDMT) included advanced age (<i>p</i> &lt; 0.001), chronic kidney disease (RASi OR 0.392, <i>p</i> = 0.008, MRA OR 0.523 <i>p</i> = 0.097), and lack of follow-up in dedicated HF clinics (<i>p</i> = 0.006). No regional differences with regards to GDMT were identified.</p> Conclusion <p>In this nation-wide real-world snapshot study, patients with chronic and acute HF accounted for a significant proportion of cardiology inpatients, while ischemic heart disease was the leading HF cause. GDMT and device therapy can be improved. Follow-up in dedicated HF units was related with increased prescription rates of GDMT, whereas this was not affected by geographical region.</p> Graphical Abstract <p>Chronic heart failure regional distribution (regional density of participants visualized on a map with person-shaped markers), comorbidities, and pharmacotherapy. HECMOS</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heart failure burden and care among cardiology inpatients: insights from the Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月22日

查看全文
  • Ioannis Leontsinis,
  • Sotiria Liori,
  • Dimitrios Farmakis,
  • Aggeliki Valatsou,
  • Panagiotis Vlachakis,
  • Christina Antonia Verikokou,
  • Ioanna Delia Vlad,
  • Vasileios Giannaris,
  • Georgios Giannopoulos,
  • Kyriakos Dimitriadis,
  • Panagiotis Theofilis,
  • Georgios Karakostas,
  • Christoforos Komporozos,
  • Georgios Konstantinides,
  • Stylianos Lambropoulos,
  • Aikaterini Lionti,
  • Athanasios Makris,
  • Panteleimon Makridis,
  • Ioannis Mamarelis,
  • Maria Marketou,
  • Aikaterini Naka,
  • Georgios Nikitas,
  • Periklis Davlouros,
  • Evaggelos Oikonomou,
  • Nikolaos Papaioannou,
  • Athanasios Pipilis,
  • Assaf Sawafta,
  • Pavlos Skantzikas,
  • Michael Siarkos,
  • Theodoros Sinanis,
  • Konstantinos Skordis,
  • Georgios Spiromitros,
  • Ioannis Stamoulopoulos,
  • Konstantinos Tsatiris,
  • Dimitrios Tsiachris,
  • Michael Fosteris,
  • Emmanouel Foukarakis,
  • Chistina Chrysochoou,
  • Gerasimos Filippatos,
  • Konstantinos Tsioufis

摘要

Purpose

Heart failure (HF) burden and care varies significantly across different countries. We aimed to illustrate the clinical characteristics and HF-related care among cardiology inpatients in Greece.

Methods

We collected information about all cardiology inpatients on the 3rd of March 2022. The current analysis focuses on acute or chronic HF.

Results

Among a total of 923 participants, 280 (30%) concerned cases of acute HF whereas 351 patients (38%), (median age 79 ± 12 years, male gender 63.8%) had a history of chronic HF, with their majority presenting with multiple comorbidities and previous HF hospitalizations. 173 (49%) of chronic HF participants had reduced LVEF. Ischemic heart disease was the predominant HF etiology (182, 51.9%). Prior to the index admission, chronic HF cases were receiving diuretics, beta blockers, ACEi/ARBs, ARNI, MRAs, and SGLT2i at 79.8%, 74.4%, 43.3%, 10.8%, 40.7%, and 14%, respectively. Independent predictors of lower prescription rates of Guideline Directed Medical Therapy (GDMT) included advanced age (p < 0.001), chronic kidney disease (RASi OR 0.392, p = 0.008, MRA OR 0.523 p = 0.097), and lack of follow-up in dedicated HF clinics (p = 0.006). No regional differences with regards to GDMT were identified.

Conclusion

In this nation-wide real-world snapshot study, patients with chronic and acute HF accounted for a significant proportion of cardiology inpatients, while ischemic heart disease was the leading HF cause. GDMT and device therapy can be improved. Follow-up in dedicated HF units was related with increased prescription rates of GDMT, whereas this was not affected by geographical region.

Graphical Abstract

Chronic heart failure regional distribution (regional density of participants visualized on a map with person-shaped markers), comorbidities, and pharmacotherapy. HECMOS